DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed non-small cell lung cancer, meeting both of the following criteria:

  • Locally advanced or metastatic (stage IIIB or IV) disease
  • Recurrent, unresectable disease
• Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan

• Previously treated with first-line platinum-based systemic chemotherapy for advanced disease AND had at least stabilization of disease as best response to first-line therapy

  • No more than one line of prior therapy
• Previously treated brain metastases allowed provided they are clinically and radiologically stable and there are no neurological symptoms or requirement for steroids

PATIENT CHARACTERISTICS:

• ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
• Life expectancy > 3 months
• Platelet count ≥ 100,000/mm³
• Leukocytes ≥ 3,000/mm³
• Absolute neutrophil count ≥ 1,500/mm³
• Hemoglobin > 9 g/dL (transfusion allowed)
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST/ALT ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)
• Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min
• Urine protein creatinine ratio ≤ 1.0 OR urine protein < 1,000 mg by 24-hour urine collection
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception prior to, during, and for 8 weeks after completion of study treatment
• No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD0530
• No QTc prolongation (i.e., QTc interval ≥ 460 msec) or other significant ECG abnormalities

• No cardiac dysfunction including, but not limited to, the following:

  • Symptomatic congestive heart failure
  • Unstable angina pectoris
  • Cardiac arrhythmia
  • History of ischemic heart disease, including myocardial infarction
• No poorly controlled hypertension (i.e., systolic blood pressure [BP] ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg)
• No condition that would impair the ability to swallow AZD0530 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication, requirement for IV alimentation, or active peptic ulcer disease)
• No concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situation that would limit compliance with study requirements

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), radiotherapy, or surgery and recovered
• Prior radiotherapy to target lesions allowed provided there is disease progression
• No prior radiotherapy to > 40% of bone marrow
• No prior EGFR tyrosine kinase inhibitors
• No prior surgical procedures affecting absorption

• No CYP3A4-active agents or substances for 7 days prior to, during, and for 7 days after completion of study treatment, including any of the following:

  • Ketoconazole
  • Itraconazole
  • Ritonavir
  • Mibefradil
  • Clarithromycin
  • Saquinavir
  • Indinavir
  • Erythromycin
  • Nefazadone
  • Fluconazole
  • Diltiazem
  • Alfentanil
  • Carbamazepine
  • Cyclosporine
  • Tacrolimus
  • Lovastatin
  • Simvastatin
• No other concurrent investigational agents
• No other concurrent anticancer therapy
• No concurrent combination antiretroviral therapy for HIV-positive patients